Profile picture

Doctor Daniel Lavall

University Hospital Leipzig, Leipzig (Germany)
Membership: FESC Member EACVI Member EAPCI Member
Follow
Logo ESC

Contributor content

SGLT2 inhibitor treatment in patients with cardiac amyloidosis
Presentation
SGLT2 inhibitor treatment in patients with cardiac amyloidosis
Left ventricular fibrosis influences the time to recovery in patients with arrhythmia-induced cardiomyopathy
Presentation
Left ventricular fibrosis influences the time to recovery in patients with arrhythmia-induced cardiomyopathy
Ventricular-arterial coupling and sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction
Presentation
Ventricular-arterial coupling and sacubitril/valsartan treatment in patients with heart failure and reduced ejection fraction
Effects of Sacubitril/Valsartan on left ventricular pressure-volume relationship in heart failure
Presentation
Effects of Sacubitril/Valsartan on left ventricular pressure-volume relationship in heart failure
Cardiac magnetic resonance T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy
Presentation
Cardiac magnetic resonance T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy
Native T1 mapping for differential diagnosis of left ventricular hypertrophy
Presentation
Native T1 mapping for differential diagnosis of left ventricular hypertrophy
Left ventricular mechanical dispersion in flow-gradient patterns of severe aortic stenosis
Presentation
Left ventricular mechanical dispersion in flow-gradient patterns of severe aortic stenosis
The non-steroidal mineralocorticoid receptor antagonist finerenone prevents structural cardiac remodeling
Presentation
The non-steroidal mineralocorticoid receptor antagonist finerenone prevents structural cardiac remodeling
Long-term hemodynamic improvement after transcatheter repair of secondary mitral regurgitation
Presentation
Long-term hemodynamic improvement after transcatheter repair of secondary mitral regurgitation
Predictors for clinical improvement after transcatheter mitral valve repair
Presentation
Predictors for clinical improvement after transcatheter mitral valve repair

ESC 365 is supported by